- Home
- AEVA vs INBX Comparison
AEVA vs INBX Comparison
Compare AEVA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEVA | INBX |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 430.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AEVA | INBX |
|---|---|---|
| Price | $13.41 | $78.97 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $26.50 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 241.1K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,154,000.00 | $1,400,000.00 |
| Revenue This Year | $87.44 | $563.00 |
| Revenue Next Year | $70.49 | $230.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 89.90 | N/A |
| 52 Week Low | $2.52 | $10.81 |
| 52 Week High | $38.80 | $94.57 |
Technical Indicators
Market Signals| Indicator | AEVA | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 49.75 |
| Support Level | $12.83 | $76.22 |
| Resistance Level | $15.73 | $94.57 |
| Average True Range (ATR) | 1.28 | 7.36 |
| MACD | -0.05 | -1.30 |
| Stochastic Oscillator | 14.67 | 28.13 |
Price Performance
Historical ComparisonAbout AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.